Treats postoperative nausea and vomiting. ANDA 205950, held by Heritage Pharma Avet. Trimethobenzamide Hydrochloride.
As of Nov 16, 2026, ANDA 205950 (Trimethobenzamide Hydrochloride), held by Heritage Pharma Avet, was first approved by FDA on Nov 21, 2023, with 0 approved supplements and 0 published complete response letters.
Trimethobenzamide hydrochloride capsules are indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. Limitation of Use: Trimethobenzamide hydrochloride capsules are not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (CNS) effects, and the risk of exacerbation of the underlying disease in pediatric patients with Reye’s syndrome or other hepatic impairment.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Trimethobenzamide Hydrochloride300MG · capsule;oral | Trimethobenzamide Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters